The great thing is Alzheimer's trials are short compared to cancer trials, so with or without breakthrough designation, starting a Phase 2b/3 trial this year means it should finish sometime in 2017, right after which 2-73 could potentially move to commercialization if results repeat what we are seeing in the 2a trial.
Market Data 
Markets 
AI
